VHL and tuberous sclerosis: This approach has previously proved successful, leading to the discovery of mizoribine and palbociclib as promising candidates for the treatment of tuberous sclerosis complex (TSC) and Von Hippel–Lindau (VHL)‐linked cancers, respectively [18, 19, 20].